Results 31 to 40 of about 19,687 (231)

Identification of proteins and cellular pathways targeted by 2-nitroimidazole hypoxic cytotoxins

open access: yesRedox Biology, 2021
Tumour hypoxia negatively impacts therapy outcomes and continues to be a major unsolved clinical problem. Nitroimidazoles are hypoxia selective compounds that become entrapped in hypoxic cells by forming drug-protein adducts.
Faisal Bin Rashed   +13 more
doaj   +1 more source

The Hepatocellular Hypoxia Criteria:2’Nitroimidazole Effect on Hepatocyte Carbohydrate Metabolizing Enzymes [PDF]

open access: yes, 2008
Aim: to understand the 2’-nitroimidazole induced hypoxia and liver cell interaction, we proposed a “Hapatocellular Hypoxia Criteria”.
Rakesh Sharma
core   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

The Structure and Activity of Double-Nitroimidazoles. A Mini-Review

open access: yesScientia Pharmaceutica, 2018
Many interesting applications have been found for nitroimidazoles as therapeutic agents. Among others, some of these compounds can radiosensitize hypoxic tumor cells.
Justyna Żwawiak, Lucjusz Zaprutko
doaj   +1 more source

68Ga‐nitroimidazole PET/CT imaging of hypoxia in tuberculosis: A case series

open access: yesJournal of Medical Radiation Sciences, 2022
Tuberculosis (TB) lesions in humans have been proven to be severely hypoxic with hypoxia leading to latency and dormancy of disease. Dormant TB lesions become less susceptible to standard TB treatment regimens with varying responses to treatment but may ...
Philippa L Bresser   +3 more
doaj   +1 more source

Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion

open access: yesDrug Delivery, 2023
Hepatocellular carcinoma (HCC) is a malignant tumor leading cancer-associated high mortality worldwide. Unfortunately, the most commonly used drug therapeutics not only lack of target ability and efficiency, but also exhibit severe systemic toxicity to ...
Congyi Zhang   +8 more
doaj   +1 more source

Comparison of the voltammetric behavior of metronidazole at a DNA-modified glassy carbon electrode, a mercury thin film electrode and a glassy carbon electrode [PDF]

open access: yes, 1997
The electroanalytical performance at three electrodes: DNA-modified galssy carbon electrode, mercury thin film electrode and glassy carbon electrode, for the study of the electrochemical reduction of metronidazole is compared. All three electrodes showed
Brett, Ana Maria Oliveira   +3 more
core   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

open access: yesBMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo   +9 more
wiley   +1 more source

2-(3-Bromophenyl)imidazo[2,1-b]oxazole

open access: yesMolbank, 2023
The microwave-assisted reaction of 2-nitroimidazole with 3-bromophenacyl bromide in the presence of potassium carbonate as a base and dimethylformamide as a solvent afforded 2-(3-bromophenyl)imidazo[2,1-b]oxazole.
Ángel Cores   +2 more
doaj   +1 more source

Imaging tumour hypoxia with positron emission tomography. [PDF]

open access: yes, 2014
Hypoxia, a hallmark of most solid tumours, is a negative prognostic factor due to its association with an aggressive tumour phenotype and therapeutic resistance.
A L Harris   +99 more
core   +2 more sources

Home - About - Disclaimer - Privacy